Making Sense of FDA’s (proposed) Rules for the Development and Approval of Biosimilars

30 May 2012, Palo Alto, United States

Introduction

This webinar will help you understand the process, requirements, quality and safety considerations for demonstrating biosimilarity to a Reference Product. You will learn about what type and how much clinical data are needed to support a showing of biosimilarity.

Venue